Pricing Log in Create free account
Saturday 17 October 2026 Export BMY’s income statement to Excel — free account

Bristol Myers Squibb Company

BMY Healthcare Drug Manufacturers General

Bristol Myers Squibb Company’s revenue for fiscal 2025 (year ended December 2025) was $48.2 billion, roughly unchanged from fiscal 2024. In the quarter to June 2026, revenue grew 5.74%, EPS grew 153.1%, free cash flow fell 13.2% and total debt fell 12.3%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for twenty-five consecutive years.

59.71 0.86 −1.42%
Market cap
$123.7B
P/E
13.2×
Fwd P/E
11.2×
Dividend yield
4.22%
F-score
8/9
Altman Z
2.14
Beneish M
−2.69
Dividend safety
63/100
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Bristol Myers Squibb Company (BMY) EBITDA

Alert me on EBITDA

Bristol Myers Squibb Company's EBITDA for fiscal 2025 was $13.3B, up 992.5% from $1.2B in fiscal 2024. Over the twelve months to 30 June 2026 it was $15.1B. Over the past ten years it has ranged from $1.2B (fiscal 2024) to $18.8B (fiscal 2021); the current reading is higher than 73% of that period. Bristol Myers Squibb Company ranks 9th of 20 Drug Manufacturers General companies by EBITDA.

EBITDA, annual

Embed this chart

Annual newest first

Period EBITDA Change
FY2025 $13.3B 992.47%
FY2024 $1.2B (93.29%)
FY2023 $18.2B 1.17%
FY2022 $18.0B (4.23%)
FY2021 $18.8B 435.31%
FY2020 $3.5B (47.79%)
FY2019 $6.7B 1.76%
FY2018 $6.6B 11.57%
FY2017 $5.9B (5.99%)
FY2016 $6.3B 156.71%

Quarterly newest first

Period EBITDA Change
Jun 2026 $4.7B 22.10%
Mar 2026 $3.8B 56.51%
Dec 2025 $2.4B (40.63%)
Sep 2025 $4.1B 48.22%
42 more quarters

Against its own ten years

Low $1.2B High $18.8B
Ten-year median $6.6B
Current reading's percentile 73

EBITDA against peers

Company EBITDA
NVO Novo Nordisk A/S compare $26.5B
NVS Novartis AG compare $22.5B
PFE Pfizer Inc. compare $20.4B
AZN AstraZeneca PLC compare $20.3B
AMGN Amgen Inc. compare $16.5B
BMY Bristol Myers Squibb Company $15.1B
GSK GSK PLC Sponsored ADR compare $12.8B
SNY Sanofi compare $10.4B
GILD Gilead Sciences, Inc. compare $262.0M

What EBITDA is

EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.

Reported line item

The full definition of EBITDA →

More on BMY